Form 4: CARGO Therapeutics Director Reid Huber Granted 25,000 Stock Options

CARGO Therapeutics, Inc. Director Reid M. Huber was granted 25,000 stock options with an exercise price of $4.35, aligning his interests with shareholders.

Summary

• Reid M. Huber, a Director of CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options.
• The transaction date for the option grant was June 18, 2025.
• The exercise price for these stock options is $4.35 per share.
• The options are set to expire on June 17, 2035.
• 100% of the shares subject to the option will vest on the earlier of (i) the one-year anniversary of June 18, 2025, or (ii) the next Annual Meeting following June 18, 2025, contingent on Mr. Huber's continued service to the Issuer.
• Following this transaction, Reid M. Huber beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a standard insider transaction (stock option grant) which is generally neutral but can be seen as slightly positive due to the alignment of director and shareholder interests.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The vesting schedule for the stock options indicates an expectation of Reid M. Huber's continued service to CARGO Therapeutics, Inc. for at least one year or until the next Annual Meeting, aligning his future incentives with the company's performance.

Management Comments

• The filing of this Form 4 by Reid M. Huber, through his attorney-in-fact, signifies a standard compensation action for a director, reflecting the company's equity incentive program.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation mechanism widely used across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to continued service, is typical for such equity grants, ensuring retention and performance alignment.
• The exercise price of $4.35, presumably the market price on the grant date, is standard for incentive stock options.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The stock options will vest on the earlier of June 18, 2026, or the next Annual Meeting following June 18, 2025, subject to Reid M. Huber's continued service.

Key Dates

Keywords

CARGO Therapeutics, CRGX, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Beneficial Ownership